MOLOGEN and ONCOLOGIE sign a term sheet on a global assignment and co-development agreement relating to MOLOGEN´s lead compound lefitolimod
(WorldNews Europe)

Publication of an inside information pursuant to Section 17 of the regulation (EU) No. 596/2014 Today, the Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, WKN A2LQ90) signed, with the consent of the Supervisory Board, a term sheet outlining the envisaged framework for a global assignment of all intellectual property and other rights in MOLOGEN`s lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global co-development agreement between MOLOGEN and ONCOLOGIE. The consideration that MOLOGEN would receive under this transaction would secure the major part of the funding for the pivotal IMPALA study on lefitolimod until the read-out projected in...